BioLife Solutions, Inc. reaffirmed 2023 revenue guidance for the fiscal 2023. For the period, the company expects revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.09 USD | -3.61% | -4.01% | +29.78% |
05-13 | Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target | MT |
05-09 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.78% | 1.01B | |
-5.31% | 182B | |
-1.21% | 114B | |
-5.53% | 67.76B | |
+1.22% | 51.91B | |
+7.03% | 43.23B | |
+6.07% | 41.07B | |
+21.96% | 32.07B | |
+15.86% | 25B | |
-4.81% | 24.55B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Reaffirms 2023 Revenue Guidance for the Fiscal 2023